SAN FRANCISCO, Sept. 3, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences:
- H.C. Wainwright 26th Annual Global Investment Conference in New York City on Monday, September 9, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time
- Stifel Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024 at 12:30 p.m. Eastern Time / 9:30 a.m. Pacific Time
The presentations will be accessible via webcast through links posted on the Investor Events section of the Nektar website: . The webcasts will be available for replay until October 9, 2024 and October 17, 2024, respectively.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit and follow us on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
View original content to download multimedia:
SOURCE Nektar Therapeutics
内克塔治疗(纳斯达克:NKTR)管理层计划在即将举行的投资者大会上进行演讲:
- H.C. Wainwright第26届全球投资大会将于2024年9月9日星期一下午3时(东部时间)/ 下午12时(太平洋时间)在纽约市举行
- Stifel虚拟免疫与炎症峰会将于2024年9月17日星期二上午12:30(东部时间)/ 上午9:30(太平洋时间)举行
演示将通过内克塔公司网站的投资者活动部分发布的链接进行访问:。 网络研讨会将分别提供重播,直到2024年10月9日和2024年10月17日。
关于内克塔治疗公司
内克塔治疗是一家专注于开发针对自身免疫和慢性炎症疾病潜在免疫功能障碍的临床生物技术公司。内克塔的主导候选药物是rezpegaldesleukin(NKTR-358),是一种新颖的、首创的调节性t细胞刺激剂,在两项第20亿阶段临床试验中正在评估,一项用于特应性皮炎,一项用于斑秃症。我们的管线还包括一种临床前候选药物NKTR-0165,是一种双价肿瘤坏死因子受体II激动剂抗体。内克塔与各种合作伙伴共同评估NKTR-255,一种旨在增强免疫系统自然抗癌能力的研究性IL-15受体激动剂,在多项正在进行的临床试验中进行评估。内克塔总部位于加利福尼亚州旧金山。欲获取更多信息,请访问 ,并关注我们的LinkedIn。
联系方式:
对于投资者:
内克塔治疗公司的Vivian Wu
628-895-0661
对于媒体人员:
Argot Partners的David Rosen
(212)600-1902
david.rosen@argotpartners.com
查看下载多媒体原始内容:
来源:内克塔治疗